Biotech businesses in California -- including those focused on drug development, medical devices and diagnostics -- brought in more than 40% of the $7.4 billion in biotech venture capital in 2006, according to a new PriceWaterhouseCoopers report. The industry's steady growth could be hampered, however, as the federal government is likely to have increased involvement in oversight of drug safety and cost-effectiveness.

Full Story:

Related Summaries